Table 2.
Patient´s baseline biochemical parameters and outcome data.
| Responders, n = 9 | Non-responders, n = 11 | P-value | |
|---|---|---|---|
| Methylene blue dose (mg/kg) | 1.3 ± 0.5 | 1.3 ± 0.4 | 0.979 |
| Low dose corticosteroids | 4 (44.4%) | 3 (27.3%) | 0.642 |
| Vasopressin | 9 (100%) | 10 (90.9%) | 1.000 |
| Inotropes | |||
| - dobutamine | 2 (22.2%) | 3 (27.3%) | 0.795 |
| - milrinone | 0 | 1 (9.1%) | 0.918 |
| - levosimendan | 0 | 1 (9.1%) | 0.918 |
| Baseline biochemical parameters | |||
| - arterial lactate (mmol/L) | 8.6 ± 5.6 | 11.4 ± 7.7 | 0.386 |
| - arterial pH | 7.26 ± 0.11 | 7.16 ± 0.10 | 0.037* |
| - base deficit (mmol/L) | 5.5 ± 5.1 | 12.9 ± 3.2 | 0.001* |
| - ScvO2 (%) | 68.6 ± 11.8 | 67.8 ± 13 | 0.821 |
| - P(v-a)CO2 gap (mmHg) | 7.84 ± 2.2 | 7.62 ± 2.42 | 0.842 |
| - P(v-a)CO2/C(a-v)O2 (mmHg/mL) | 1.79 ± 0.73 | 3.24 ± 1.18 | 0.007* |
| - ionized calcium (mmol/L) | 0.90 ± 0.05 | 0.94 ± 0.13 | 0.517 |
| SOFA score | 14.2 ± 3.0 | 14.9 ± 1.8 | 0.556 |
| APACHE II score | 31.3 ± 4.7 | 32.1 ± 3.9 | 0.703 |
| Mortality within 24 hours | 0 | 5 (45.5%) | 0.038* |
| ICU mortality | 4 (44.4%) | 11 (100%) | 0.008* |
| 30-day mortality | 4 (44.4%) | 11 (100%) | 0.008* |
| ICU length of stay (days) | 12.6 ± 11.9 | 2.5 ± 3.3 | 0.015* |
| Duration of mechanical ventilation (hours) | 135 ± 111 | 51 ± 64 | 0.047* |
| ARDS | 1 (11.1%) | 2 (18.2%) | 1.000 |
| AKI | 8 (88.9%) | 9 (81.8%) | 1.000 |
| CRRT | 2 (22.2%) | 2 (18.2%) | 1.000 |
| VA-ECMO | 2 (22.2%) | 0 | 0.189 |
ScvO2, central venous oxygen saturation; P(v-a) CO2 gap, venous-to-arterial carbon dioxide tension difference; P(v-a)CO2/C(a-v)O2, ratio of venous-to-arterial carbon dioxide tension to arterio-venous oxygen content; SOFA, Sequential organ failure assessment; APACHE II, Acute physiology and chronic health assessment; ICU, intensive care unit; ARDS, Adult respiratory distress syndrome; AKI, acute kidney injury; CRRT, continuous renal replacement therapy; VA-ECMO, veno-arterial extracorporeal membrane oxygenation.
*P < 0.05.